



ASX Announcement

11 February 2020

## **Creso to launch a new hemp plant product for equines and large animals**

### **Highlights**

- Creso Pharma has successfully developed anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals
- anibidiol®EQUI is a natural plant product aimed at reducing stress and pain and supporting fast mobility recovery
- The product was developed with Switzerland-based CapService over the last 12 months

**Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** is pleased to announce that it plans to launch a new hemp derived animal health product targeted at equines and large animals in the second half of 2020.

Developed over the past 12 months, anibidiol®EQUI is a flavoured micromilled hemp plant product for large animals, and in particular horses.

The complementary feed anibidiol®EQUI is based on natural hemp plant components and provides the entourage effect in which the various hemp components work together to strengthen the key benefits, aiming to reduce stress and pain and support fast mobility recovery.

The product contains natural hemp compounds which are recognised as traditional feed components already approved for use in consumer products. This represents an additional pathway to market for the Company's hemp-based complementary feed products without the need for regulatory approval.

anibidiol®EQUI will be mainly commercialised in LATAM, ASIAPAC and selected European countries, thus increasing the Company's global commercial foot print.



anibidiol®EQUI is Swiss made, produced out of Swiss Good Agricultural Practice (GAP) compliant industrial hemp.

**Dr. Miri Halperin Wernli, Co-Founder and CEO said:** “Creso Pharma is excited to add another innovative product to our growing portfolio. anibidiol®EQUI was developed to address the equines and large animals’ needs for a natural plant based complementary feed product to support the management of stress and pain and to enhance well-being. We are pleased to have this product ready for launch later this year.”

**Ends**

#### **Authority and Contact Details**

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

#### **Investor Enquiries**

EverBlu Capital  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000

#### **Media Enquiries**

Julia Maguire | The Capital Network  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)  
P: +61 419 815 386

#### **About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.



Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

### **Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.